MAPT and early-onset autosomal dominant Alzheimer disease: How do different proposed measurements of tau brain pathologic abnormalities (ie, levels of phosphorylated tau 181 in the cerebrospinal fluid [CSF]) and neurodegeneration (ie, total tau levels in the CSF and brain atrophy) change over the course of Alzheimer disease?